Tafasitamab: Final Results of Five-Year Safety and Efficacy Study (Phase II L-MIND) Prof. Kalakonda - Synopsis below extracted from the video transcript.
The final results of a five-year safety and efficacy study of tafasitamab, a monoclonal antibody used for the treatment of diffuse large B-cell lymphoma (DLBCL). The study was conducted in a Phase II clinical trial called L-MIND, which included patients with relapsed or refractory DLBCL who had received at least two prior lines of therapy.
Professor Nagesh Kalakonda, a medical oncologist, discusses the key findings of the study. The overall response rate (ORR) was 58%, with a complete response (CR) rate of 43%. This demonstrates the efficacy of tafasitamab in treating patients with relapsed or refractory DLBCL. The median duration of response was found to be 34.6 months, indicating that patients who respond to tafasitamab may have long-lasting responses.
The safety profile of tafasitamab was also evaluated in the study. The most common adverse events observed were infections and neutropenia. However, these were generally manageable with appropriate treatment. The incidence of cytokine release syndrome (CRS) was low, with only 5% of patients experiencing grade 3 or higher CRS.
Furthermore, the study explored the impact of different patient characteristics on the response to tafasitamab. It was found that patients with a non-GCB (germinal center B-cell) subtype of DLBCL and high expression of the CD79b antigen responded better to tafasitamab treatment.
In conclusion, the L-MIND study demonstrated that tafasitamab is an effective and safe treatment option for patients with relapsed or refractory DLBCL. The long duration of response observed in the study highlights the potential for long-term benefits from tafasitamab treatment. Additionally, the study provides insights into patient characteristics that may impact the response to tafasitamab, which can help identify the patients who are most likely to benefit from this treatment.
